Johan Edvard Steineger
- Consultant; PhD
- +47 23 07 16 97
Publications 2023
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Laryngoscope Investig Otolaryngol, 9 (1), e1196
DOI 10.1002/lio2.1196, PubMed 38362186
[A child with periorbital swelling]
Tidsskr Nor Laegeforen, 143 (4)
DOI 10.4045/tidsskr.22.0434, PubMed 36919299
Publications 2021
A comparative study of two grading systems for epistaxis in hereditary haemorrhagic telangiectasia
Rhinology, 59 (2), 212-218
DOI 10.4193/Rhin20.540, PubMed 33821857
Publications 2020
Otorhinolaryngologists and the SARS-CoV-2 virus
Tidsskr Nor Laegeforen, 140 (10)
DOI 10.4045/tidsskr.20.0423, PubMed 32602325
Otorhinolaryngologists and the SARS-CoV-2 virus
Tidsskr. Nor. Laegeforen., 140 (10), 966-967
Publications 2019
Intranasal bevacizumab injections improve quality of life in HHT patients
Laryngoscope, 130 (5), E284-E288
DOI 10.1002/lary.28179, PubMed 31287573
Publications 2018
Mucous membrane pemphigoid
Tidsskr. Nor. Laegeforen., 138 (2), 153
[Mucosal pemphigoid]
Tidsskr Nor Laegeforen, 138 (2)
DOI 10.4045/tidsskr.17.0557, PubMed 29357643
Long-term experience with intranasal bevacizumab therapy
Laryngoscope, 128 (10), 2237-2244
DOI 10.1002/lary.27147, PubMed 29469958
Pentraxin 3 level is elevated in hereditary hemorrhagic telangiectasia and reflects the severity of disease-associated epistaxis
Laryngoscope, 129 (1), E44-E49
DOI 10.1002/lary.27548, PubMed 30329172
Publications 2017
Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
Laryngoscope, 128 (3), 593-596
DOI 10.1002/lary.26722, PubMed 28671294